Lung Cancer Therapeutics Market Overview (2022 to 2032)
The global lung cancer therapeutics market share is projected to reach US$ 48,725.9 Million by 2026, exhibiting a CAGR of 13.4% in the forecast period.
Lung cancer diagnoses have increased as a result of increased cancer awareness in both advanced and emerging economies, as well as the introduction of new medical diagnostic equipment and improved treatments, propelling the lung cancer therapeutics market forward.
This, along with increased spending in research and innovation by leading players, is fueling the demand for lung cancer therapeutics. The shift in the market is mostly due to a higher focus on research projects as a result of the rising incidence of lung cancer.
Report Attribute
Details
Expected Market Value (2026)
US$ 48,725.9 Million
Projected Growth Rate (2022 to 2032)
13.4% CAGR
The worldwide lung cancer therapeutics market is predicted to grow at a high rate as the incidence of lung cancer rises. The global lung cancer therapeutics market is being driven by a growing demand for tailored therapy, the availability of highly effective medications, an increase in the elderly population, and an increase in the prevalence of unhealthy lifestyles.
The introduction of nanomedicine to treat lung cancer and the growing number of approvals in the lung cancer treatments market are driving the demand for lung cancer therapeutics.
With rising regulatory approvals and the acceptance of modern treatments in Europe, the lung cancer therapeutics market is predicted to develop.
In growing economies such as China and India, however, the surge in lung disease prevalence and the dominance of chemotherapy are driving the growth of the lung cancer therapeutics market. Advanced immunotherapies and tailored medicines are becoming more expensive in countries like Japan, thus limiting the demand for lung cancer therapeutics.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
What are the Key Contributors to the Demand for Lung Cancer Therapeutics?
Lung cancer is a malignant tumor characterized by the uncontrolled growth of cell tissues in the lung. It is the second most commonly diagnosed and has the highest mortality rate of all cancers in both men and women. Thus, with the rise in the incidence rate of lung cancer, the demand for lung cancer therapeutics is also expected to grow during the study period.
Increasing incidences of lung cancer due to the rising smoking population is one of the major factors driving the growth of the lung cancer therapeutics market. The risk of lung cancer is tenfold higher in smokers as compared to non-smokers.
The launch of premium-priced drugs and new innovative radiation therapies coupled with rising incidences of NSCLC is the major driving factors for the growth of the lung cancer therapeutics market. However, the generalization of the major drugs might restrict the demand for lung cancer therapeutics.
How is the Lung Cancer Therapeutics Market Segmented?
Based on the cancer cell types, lung cancer is broadly segmented as small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC segment accounts for approximately 80 to 90% of all lung cancers.
Based on the cell shape and size, NSCLC is further divided into three subtypes they are adenocarcinoma, large-cell carcinoma, and squamous cell carcinoma. These NSCLCs are primarily treated with surgeries. At the same time, chemotherapy is increasingly used for both the pre-operative and post-operative treatment of patients.
The treatment options available for the NSCLC include surgery, radiation therapy, and chemotherapy. The top five global brands that are commercially available in the market are Avastin, Tarceva, Alimta, Gemzar, and Taxotere. Thus, all the above-mentioned factors collectively drive the growth of the global lung cancer therapeutics market.
Find your sweet spots for generating winning opportunities in this market.
Which Region Dominates the Lung Cancer Therapeutics Market?
Geographically, North America and Europe dominate the global lung cancer therapeutics market. According to Lung Disease Research Funding, approximately 75,000 people in the USA die because of lung injury every year.
The USA is the largest market for NSCLC owing to the high incidence rate rise in the aging population. In addition, with the advent of new treatment therapies such as targeted drug therapy, stereotactic are aiding the growth of the lung cancer therapeutics market share.
Europe accounts for the highest demand for lung cancer therapeutics after North America. At the same time, Asia-Pacific countries such as India and China, and South East Asia are the emerging regions for the global lung cancer therapeutics market due to the high prevalence of this disease coupled with increasing healthcare awareness.
How is the Competitive Landscape in the Lung Cancer Therapeutics Market?
Players are adopting various strategies to expand their product portfolio and increase their geographical presence for demand for lung cancer therapeutics. Some of the key strategies used by players in the global lung cancer therapeutics market include product innovation, partnerships and alliances, and mergers.
The prominent leading players of driving the lung cancer therapeutics market share include AstraZeneca Lc, Eli Lilly, and Company, GlaxoSmithKline, Hoffman-La Roche, Boehringer Ingelheim GmbH, Pfizer Inc., and Sanofi-Aventis, among others.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Scope Of Report
Report Attributes
Details
Growth rate
CAGR of 13.4% from 2022 to 2030
The base year for estimation
2021
Historical data
2015 to 2020
Forecast period
2022 to 2032
Quantitative units
Revenue in USD Million, volume in kilotons, and CAGR from 2022 to 2032
Report Coverage
Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis,
Segments Covered
Product, application, region
Regional scope
North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia, and New Zealand
Country scope
USA; Canada; Mexico; Germany; United Kingdom; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; United Arab Emirates(UAE); Iran; South Africa
Key companies profiled
AstrazenecaPlc, Sanofi-Aventis., GlaxoSmitKline, Eli Lilly and Company, BoehringerIngelheim GmbH, Pfizer Inc., Hoffman-La Roche
Customization scope
Free report customization (equivalent to up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs.
Key Segments
By Cancer Cell Type:
Small Lung Cancer
Non-Small Lung Cancer (NSLC)
By Molecule Type:
Biologics
Small Molecules
By Mode of Administration:
Injectable
Oral
By Type:
AML
CML
ALL
CLL
By Region:
North America
Latin America
Europe
Asia Pacific
Middle East and Africa(MEA)
Frequently Asked Questions
Which Therapy Attracts the Highest Demand for the Lung Cancer Therapeutics Market?
Targeted therapy is the leading segment in the lung cancer therapeutics market.
What is the Growth Outlook for the Lung Cancer Therapeutics Market?
Demand for lung cancer therapeutics is projected to advance at a CAGR of 13.4% during the forecast period.
Which Region has the Most Share in the Lung Cancer Therapeutics Market?
North America has the highest lung cancer therapeutics market share.
Table of Content
1. Executive Summary | Lung Cancer Therapeutics Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. Value Chain Analysis
3.5.1. Profit Margin Analysis
3.5.2. Service Providers
3.6. PESTLE and Porter's Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2022 to 2032
5.3.1. Chemotherapy
5.3.2. Targeted Therapy
5.3.3. Radiotherapy
5.3.4. Biological Therapy
5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Treatment Type, 2022 to 2032 Deep-dive segmentation will be available in the sample on request
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Disease Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2022 to 2032
6.3.1. Non-small Cell Lung Cancer (NSCLC)
6.3.2. Small Cell Lung Cancer (SCLC)
6.4. Y-o-Y Growth Trend Analysis By Disease Type, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Disease Type, 2022 to 2032 Deep-dive segmentation will be available in the sample on request
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Drug Class
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2017 to 2021
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2022 to 2032
7.3.1. Immunosuppressant
7.3.2. Monoclonal Antibodies
7.3.3. Tyrosine Kinase
7.3.4. Epidermal Growth Factors Receptors
7.3.5. Topoisomerase Inhibitors
7.3.6. Others
7.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017 to 2021
7.5. Absolute $ Opportunity Analysis By Drug Class, 2022 to 2032 Deep-dive segmentation will be available in the sample on request
8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Route of Administration
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2017 to 2021
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2022 to 2032
8.3.1. Oral
8.3.2. Injectable
8.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017 to 2021
8.5. Absolute $ Opportunity Analysis By Route of Administration, 2022 to 2032 Deep-dive segmentation will be available in the sample on request
9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Distribution Channel
9.1. Introduction / Key Findings
9.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2017 to 2021
9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2022 to 2032
9.3.1. Hospital
9.3.2. Specialty Clinics
9.3.3. Clinical Research Institutes
9.3.4. Home Care Settings
9.3.5. Ambulatory Surgical Centers
9.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017 to 2021
9.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022 to 2032 Deep-dive segmentation will be available in the sample on request
10. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
10.1. Introduction
10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021
10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. East Asia
10.3.5. South Asia & Pacific
10.3.6. Middle East and Africa
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. USA
11.2.1.2. Canada
11.2.2. By Treatment Type
11.2.3. By Disease Type
11.2.4. By Drug Class
11.2.5. By Route of Administration
11.2.6. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment Type
11.3.3. By Disease Type
11.3.4. By Drug Class
11.3.5. By Route of Administration
11.3.6. By Distribution Channel
11.4. Key Takeaways
12. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. Mexico
12.2.1.2. Brazil
12.2.1.3. Rest of Latin America
12.2.2. By Treatment Type
12.2.3. By Disease Type
12.2.4. By Drug Class
12.2.5. By Route of Administration
12.2.6. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment Type
12.3.3. By Disease Type
12.3.4. By Drug Class
12.3.5. By Route of Administration
12.3.6. By Distribution Channel
12.4. Key Takeaways
13. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. Germany
13.2.1.2. Italy
13.2.1.3. France
13.2.1.4. United Kingdom
13.2.1.5. Spain
13.2.1.6. BENELUX
13.2.1.7. Russia
13.2.1.8. Rest of Europe
13.2.2. By Treatment Type
13.2.3. By Disease Type
13.2.4. By Drug Class
13.2.5. By Route of Administration
13.2.6. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment Type
13.3.3. By Disease Type
13.3.4. By Drug Class
13.3.5. By Route of Administration
13.3.6. By Distribution Channel
13.4. Key Takeaways
14. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Treatment Type
14.2.3. By Disease Type
14.2.4. By Drug Class
14.2.5. By Route of Administration
14.2.6. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment Type
14.3.3. By Disease Type
14.3.4. By Drug Class
14.3.5. By Route of Administration
14.3.6. By Distribution Channel
14.4. Key Takeaways
15. South Asia & Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
15.2.1. By Country
15.2.1.1. India
15.2.1.2. ASEAN
15.2.1.3. Australia and New Zealand
15.2.1.4. Rest of South Asia & Pacific
15.2.2. By Treatment Type
15.2.3. By Disease Type
15.2.4. By Drug Class
15.2.5. By Route of Administration
15.2.6. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Treatment Type
15.3.3. By Disease Type
15.3.4. By Drug Class
15.3.5. By Route of Administration
15.3.6. By Distribution Channel
15.4. Key Takeaways
16. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. Turkey
16.2.1.3. South Africa
16.2.1.4. Rest of Middle East and Africa
16.2.2. By Treatment Type
16.2.3. By Disease Type
16.2.4. By Drug Class
16.2.5. By Route of Administration
16.2.6. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Treatment Type
16.3.3. By Disease Type
16.3.4. By Drug Class
16.3.5. By Route of Administration
16.3.6. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2021
17.1.2.1. By Treatment Type
17.1.2.2. By Disease Type
17.1.2.3. By Drug Class
17.1.2.4. By Route of Administration
17.1.2.5. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2021
17.2.2.1. By Treatment Type
17.2.2.2. By Disease Type
17.2.2.3. By Drug Class
17.2.2.4. By Route of Administration
17.2.2.5. By Distribution Channel
17.3. Mexico
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2021
17.3.2.1. By Treatment Type
17.3.2.2. By Disease Type
17.3.2.3. By Drug Class
17.3.2.4. By Route of Administration
17.3.2.5. By Distribution Channel
17.4. Brazil
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2021
17.4.2.1. By Treatment Type
17.4.2.2. By Disease Type
17.4.2.3. By Drug Class
17.4.2.4. By Route of Administration
17.4.2.5. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2021
17.5.2.1. By Treatment Type
17.5.2.2. By Disease Type
17.5.2.3. By Drug Class
17.5.2.4. By Route of Administration
17.5.2.5. By Distribution Channel
17.6. Italy
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2021
17.6.2.1. By Treatment Type
17.6.2.2. By Disease Type
17.6.2.3. By Drug Class
17.6.2.4. By Route of Administration
17.6.2.5. By Distribution Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2021
17.7.2.1. By Treatment Type
17.7.2.2. By Disease Type
17.7.2.3. By Drug Class
17.7.2.4. By Route of Administration
17.7.2.5. By Distribution Channel
17.8. United Kingdom
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2021
17.8.2.1. By Treatment Type
17.8.2.2. By Disease Type
17.8.2.3. By Drug Class
17.8.2.4. By Route of Administration
17.8.2.5. By Distribution Channel
17.9. Spain
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2021
17.9.2.1. By Treatment Type
17.9.2.2. By Disease Type
17.9.2.3. By Drug Class
17.9.2.4. By Route of Administration
17.9.2.5. By Distribution Channel
17.10. BENELUX
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2021
17.10.2.1. By Treatment Type
17.10.2.2. By Disease Type
17.10.2.3. By Drug Class
17.10.2.4. By Route of Administration
17.10.2.5. By Distribution Channel
17.11. Russia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2021
17.11.2.1. By Treatment Type
17.11.2.2. By Disease Type
17.11.2.3. By Drug Class
17.11.2.4. By Route of Administration
17.11.2.5. By Distribution Channel
17.12. China
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2021
17.12.2.1. By Treatment Type
17.12.2.2. By Disease Type
17.12.2.3. By Drug Class
17.12.2.4. By Route of Administration
17.12.2.5. By Distribution Channel
17.13. Japan
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2021
17.13.2.1. By Treatment Type
17.13.2.2. By Disease Type
17.13.2.3. By Drug Class
17.13.2.4. By Route of Administration
17.13.2.5. By Distribution Channel
17.14. South Korea
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2021
17.14.2.1. By Treatment Type
17.14.2.2. By Disease Type
17.14.2.3. By Drug Class
17.14.2.4. By Route of Administration
17.14.2.5. By Distribution Channel
17.15. India
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2021
17.15.2.1. By Treatment Type
17.15.2.2. By Disease Type
17.15.2.3. By Drug Class
17.15.2.4. By Route of Administration
17.15.2.5. By Distribution Channel
17.16. ASIAN
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2021
17.16.2.1. By Treatment Type
17.16.2.2. By Disease Type
17.16.2.3. By Drug Class
17.16.2.4. By Route of Administration
17.16.2.5. By Distribution Channel
17.17. Australia and New Zealand
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2021
17.17.2.1. By Treatment Type
17.17.2.2. By Disease Type
17.17.2.3. By Drug Class
17.17.2.4. By Route of Administration
17.17.2.5. By Distribution Channel
17.18. GCC Countries
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2021
17.18.2.1. By Treatment Type
17.18.2.2. By Disease Type
17.18.2.3. By Drug Class
17.18.2.4. By Route of Administration
17.18.2.5. By Distribution Channel
17.19. Turkey
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2021
17.19.2.1. By Treatment Type
17.19.2.2. By Disease Type
17.19.2.3. By Drug Class
17.19.2.4. By Route of Administration
17.19.2.5. By Distribution Channel
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2021
17.20.2.1. By Treatment Type
17.20.2.2. By Disease Type
17.20.2.3. By Drug Class
17.20.2.4. By Route of Administration
17.20.2.5. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Treatment Type
18.3.3. By Disease Type
18.3.4. By Drug Class
18.3.5. By Route of Administration
18.3.6. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. F. Hoffmann-La Roche Ltd
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.1.5.2. Product Strategy
19.1.1.5.3. Channel Strategy
19.1.2. GlaxoSmithKline plc.
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.2.5.2. Product Strategy
19.1.2.5.3. Channel Strategy
19.1.3. Merck & Co.
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.3.5.2. Product Strategy
19.1.3.5.3. Channel Strategy
19.1.4. Agennix AG
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.4.5.2. Product Strategy
19.1.4.5.3. Channel Strategy
19.1.5. Boehringer Ingelheim GmbH
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.5.5.2. Product Strategy
19.1.5.5.3. Channel Strategy
19.1.6. Sanofi-Aventis
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.6.5.2. Product Strategy
19.1.6.5.3. Channel Strategy
19.1.7. Eli Lilly and Company
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.7.5.2. Product Strategy
19.1.7.5.3. Channel Strategy
19.1.8. Celgene Corporation
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.8.5.2. Product Strategy
19.1.8.5.3. Channel Strategy
20. Assumptions & Acronyms Used21. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2032
Table 2: Global Market Value (US$ Million) Forecast by Treatment Type, 2017 to 2032
Table 3: Global Market Value (US$ Million) Forecast by Disease Type, 2017 to 2032
Table 4: Global Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 5: Global Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 6: Global Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 7: North America Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 8: North America Market Value (US$ Million) Forecast by Treatment Type, 2017 to 2032
Table 9: North America Market Value (US$ Million) Forecast by Disease Type, 2017 to 2032
Table 10: North America Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 11: North America Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 12: North America Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 13: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 14: Latin America Market Value (US$ Million) Forecast by Treatment Type, 2017 to 2032
Table 15: Latin America Market Value (US$ Million) Forecast by Disease Type, 2017 to 2032
Table 16: Latin America Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 17: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 18: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 19: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 20: Europe Market Value (US$ Million) Forecast by Treatment Type, 2017 to 2032
Table 21: Europe Market Value (US$ Million) Forecast by Disease Type, 2017 to 2032
Table 22: Europe Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 23: Europe Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 24: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 25: East Asia Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 26: East Asia Market Value (US$ Million) Forecast by Treatment Type, 2017 to 2032
Table 27: East Asia Market Value (US$ Million) Forecast by Disease Type, 2017 to 2032
Table 28: East Asia Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 29: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 30: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 31: South Asia & Pacific Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 32: South Asia & Pacific Market Value (US$ Million) Forecast by Treatment Type, 2017 to 2032
Table 33: South Asia & Pacific Market Value (US$ Million) Forecast by Disease Type, 2017 to 2032
Table 34: South Asia & Pacific Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 35: South Asia & Pacific Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 36: South Asia & Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 37: MEA Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 38: MEA Market Value (US$ Million) Forecast by Treatment Type, 2017 to 2032
Table 39: MEA Market Value (US$ Million) Forecast by Disease Type, 2017 to 2032
Table 40: MEA Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 41: MEA Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 42: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Treatment Type, 2022 to 2032
Figure 2: Global Market Value (US$ Million) by Disease Type, 2022 to 2032
Figure 3: Global Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 4: Global Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 5: Global Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 6: Global Market Value (US$ Million) by Region, 2022 to 2032
Figure 7: Global Market Value (US$ Million) Analysis by Region, 2017 to 2032
Figure 8: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032
Figure 9: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032
Figure 10: Global Market Value (US$ Million) Analysis by Treatment Type, 2017 to 2032
Figure 11: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2022 to 2032
Figure 12: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2022 to 2032
Figure 13: Global Market Value (US$ Million) Analysis by Disease Type, 2017 to 2032
Figure 14: Global Market Value Share (%) and BPS Analysis by Disease Type, 2022 to 2032
Figure 15: Global Market Y-o-Y Growth (%) Projections by Disease Type, 2022 to 2032
Figure 16: Global Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 17: Global Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 18: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 19: Global Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 20: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 21: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 22: Global Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 23: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 24: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 25: Global Market Attractiveness by Treatment Type, 2022 to 2032
Figure 26: Global Market Attractiveness by Disease Type, 2022 to 2032
Figure 27: Global Market Attractiveness by Drug Class, 2022 to 2032
Figure 28: Global Market Attractiveness by Route of Administration, 2022 to 2032
Figure 29: Global Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 30: Global Market Attractiveness by Region, 2022 to 2032
Figure 31: North America Market Value (US$ Million) by Treatment Type, 2022 to 2032
Figure 32: North America Market Value (US$ Million) by Disease Type, 2022 to 2032
Figure 33: North America Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 34: North America Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 35: North America Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 36: North America Market Value (US$ Million) by Country, 2022 to 2032
Figure 37: North America Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 38: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 39: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 40: North America Market Value (US$ Million) Analysis by Treatment Type, 2017 to 2032
Figure 41: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2022 to 2032
Figure 42: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2022 to 2032
Figure 43: North America Market Value (US$ Million) Analysis by Disease Type, 2017 to 2032
Figure 44: North America Market Value Share (%) and BPS Analysis by Disease Type, 2022 to 2032
Figure 45: North America Market Y-o-Y Growth (%) Projections by Disease Type, 2022 to 2032
Figure 46: North America Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 47: North America Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 48: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 49: North America Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 50: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 51: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 52: North America Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 53: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 54: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 55: North America Market Attractiveness by Treatment Type, 2022 to 2032
Figure 56: North America Market Attractiveness by Disease Type, 2022 to 2032
Figure 57: North America Market Attractiveness by Drug Class, 2022 to 2032
Figure 58: North America Market Attractiveness by Route of Administration, 2022 to 2032
Figure 59: North America Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 60: North America Market Attractiveness by Country, 2022 to 2032
Figure 61: Latin America Market Value (US$ Million) by Treatment Type, 2022 to 2032
Figure 62: Latin America Market Value (US$ Million) by Disease Type, 2022 to 2032
Figure 63: Latin America Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 64: Latin America Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 65: Latin America Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 66: Latin America Market Value (US$ Million) by Country, 2022 to 2032
Figure 67: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 68: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 69: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 70: Latin America Market Value (US$ Million) Analysis by Treatment Type, 2017 to 2032
Figure 71: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2022 to 2032
Figure 72: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2022 to 2032
Figure 73: Latin America Market Value (US$ Million) Analysis by Disease Type, 2017 to 2032
Figure 74: Latin America Market Value Share (%) and BPS Analysis by Disease Type, 2022 to 2032
Figure 75: Latin America Market Y-o-Y Growth (%) Projections by Disease Type, 2022 to 2032
Figure 76: Latin America Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 77: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 78: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 79: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 80: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 81: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 82: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 83: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 84: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 85: Latin America Market Attractiveness by Treatment Type, 2022 to 2032
Figure 86: Latin America Market Attractiveness by Disease Type, 2022 to 2032
Figure 87: Latin America Market Attractiveness by Drug Class, 2022 to 2032
Figure 88: Latin America Market Attractiveness by Route of Administration, 2022 to 2032
Figure 89: Latin America Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 90: Latin America Market Attractiveness by Country, 2022 to 2032
Figure 91: Europe Market Value (US$ Million) by Treatment Type, 2022 to 2032
Figure 92: Europe Market Value (US$ Million) by Disease Type, 2022 to 2032
Figure 93: Europe Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 94: Europe Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 95: Europe Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 96: Europe Market Value (US$ Million) by Country, 2022 to 2032
Figure 97: Europe Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 98: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 99: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 100: Europe Market Value (US$ Million) Analysis by Treatment Type, 2017 to 2032
Figure 101: Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2022 to 2032
Figure 102: Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2022 to 2032
Figure 103: Europe Market Value (US$ Million) Analysis by Disease Type, 2017 to 2032
Figure 104: Europe Market Value Share (%) and BPS Analysis by Disease Type, 2022 to 2032
Figure 105: Europe Market Y-o-Y Growth (%) Projections by Disease Type, 2022 to 2032
Figure 106: Europe Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 107: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 108: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 109: Europe Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 110: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 111: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 112: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 113: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 114: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 115: Europe Market Attractiveness by Treatment Type, 2022 to 2032
Figure 116: Europe Market Attractiveness by Disease Type, 2022 to 2032
Figure 117: Europe Market Attractiveness by Drug Class, 2022 to 2032
Figure 118: Europe Market Attractiveness by Route of Administration, 2022 to 2032
Figure 119: Europe Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 120: Europe Market Attractiveness by Country, 2022 to 2032
Figure 121: East Asia Market Value (US$ Million) by Treatment Type, 2022 to 2032
Figure 122: East Asia Market Value (US$ Million) by Disease Type, 2022 to 2032
Figure 123: East Asia Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 124: East Asia Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 125: East Asia Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 126: East Asia Market Value (US$ Million) by Country, 2022 to 2032
Figure 127: East Asia Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 128: East Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 129: East Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 130: East Asia Market Value (US$ Million) Analysis by Treatment Type, 2017 to 2032
Figure 131: East Asia Market Value Share (%) and BPS Analysis by Treatment Type, 2022 to 2032
Figure 132: East Asia Market Y-o-Y Growth (%) Projections by Treatment Type, 2022 to 2032
Figure 133: East Asia Market Value (US$ Million) Analysis by Disease Type, 2017 to 2032
Figure 134: East Asia Market Value Share (%) and BPS Analysis by Disease Type, 2022 to 2032
Figure 135: East Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2022 to 2032
Figure 136: East Asia Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 137: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 138: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 139: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 140: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 141: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 142: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 143: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 144: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 145: East Asia Market Attractiveness by Treatment Type, 2022 to 2032
Figure 146: East Asia Market Attractiveness by Disease Type, 2022 to 2032
Figure 147: East Asia Market Attractiveness by Drug Class, 2022 to 2032
Figure 148: East Asia Market Attractiveness by Route of Administration, 2022 to 2032
Figure 149: East Asia Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 150: East Asia Market Attractiveness by Country, 2022 to 2032
Figure 151: South Asia & Pacific Market Value (US$ Million) by Treatment Type, 2022 to 2032
Figure 152: South Asia & Pacific Market Value (US$ Million) by Disease Type, 2022 to 2032
Figure 153: South Asia & Pacific Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 154: South Asia & Pacific Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 155: South Asia & Pacific Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 156: South Asia & Pacific Market Value (US$ Million) by Country, 2022 to 2032
Figure 157: South Asia & Pacific Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 158: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 159: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 160: South Asia & Pacific Market Value (US$ Million) Analysis by Treatment Type, 2017 to 2032
Figure 161: South Asia & Pacific Market Value Share (%) and BPS Analysis by Treatment Type, 2022 to 2032
Figure 162: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Treatment Type, 2022 to 2032
Figure 163: South Asia & Pacific Market Value (US$ Million) Analysis by Disease Type, 2017 to 2032
Figure 164: South Asia & Pacific Market Value Share (%) and BPS Analysis by Disease Type, 2022 to 2032
Figure 165: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Disease Type, 2022 to 2032
Figure 166: South Asia & Pacific Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 167: South Asia & Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 168: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 169: South Asia & Pacific Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 170: South Asia & Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 171: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 172: South Asia & Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 173: South Asia & Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 174: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 175: South Asia & Pacific Market Attractiveness by Treatment Type, 2022 to 2032
Figure 176: South Asia & Pacific Market Attractiveness by Disease Type, 2022 to 2032
Figure 177: South Asia & Pacific Market Attractiveness by Drug Class, 2022 to 2032
Figure 178: South Asia & Pacific Market Attractiveness by Route of Administration, 2022 to 2032
Figure 179: South Asia & Pacific Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 180: South Asia & Pacific Market Attractiveness by Country, 2022 to 2032
Figure 181: MEA Market Value (US$ Million) by Treatment Type, 2022 to 2032
Figure 182: MEA Market Value (US$ Million) by Disease Type, 2022 to 2032
Figure 183: MEA Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 184: MEA Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 185: MEA Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 186: MEA Market Value (US$ Million) by Country, 2022 to 2032
Figure 187: MEA Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 188: MEA Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 189: MEA Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 190: MEA Market Value (US$ Million) Analysis by Treatment Type, 2017 to 2032
Figure 191: MEA Market Value Share (%) and BPS Analysis by Treatment Type, 2022 to 2032
Figure 192: MEA Market Y-o-Y Growth (%) Projections by Treatment Type, 2022 to 2032
Figure 193: MEA Market Value (US$ Million) Analysis by Disease Type, 2017 to 2032
Figure 194: MEA Market Value Share (%) and BPS Analysis by Disease Type, 2022 to 2032
Figure 195: MEA Market Y-o-Y Growth (%) Projections by Disease Type, 2022 to 2032
Figure 196: MEA Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 197: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 198: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 199: MEA Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 200: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 201: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 202: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 203: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 204: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 205: MEA Market Attractiveness by Treatment Type, 2022 to 2032
Figure 206: MEA Market Attractiveness by Disease Type, 2022 to 2032
Figure 207: MEA Market Attractiveness by Drug Class, 2022 to 2032
Figure 208: MEA Market Attractiveness by Route of Administration, 2022 to 2032
Figure 209: MEA Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 210: MEA Market Attractiveness by Country, 2022 to 2032
